- DEINOVE will present DNV3837/DNV3681, its antibiotic candidate targeting both urgent threats to public health and bioterrorism pathogens.
- BARDA coordinates the United States Government’s efforts to assess, prevent, protect against, respond to, and recover from biological incidents.
- DEINOVE will present the progress of its drug candidate’s various programs at the Lightning Talks at the BARDA annual conference.
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces that it has been selected to present its first-in-class antibiotic candidate DNV3837/DNV3681 at BARDA Industry Day 2019, in Washington DC on October 16.
DEINOVE is one of the very few European companies selected for the Lightning Talks and will discuss about “DNV3837/DNV3681, a novel class of quinolonyl-oxazolidinone antibacterials targeting both urgent threats to public health and bioterrorism pathogens.”
Full PR available here